查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1365835

抗生素抗藥性市場：按藥物類別、病原體、適應症​​和作用方式分類：2023-2032年全球機會分析和產業預測

Antimicrobial Resistance Market By Drug Class, By Pathogen, By Indication, By Mechanism of Action : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 389 Pages | 商品交期: 2-3個工作天內

價格

由於製藥業市場需求的增加，預計2023年至2032年抗生素抗藥性市場將出現7.6%的顯著成長率。

抗菌素抗藥性市場-IMG1

由於微生物繁殖週期中發生的基因變化，抗生素抗藥性通常會隨著時間的推移而產生。 DNA 的變化可以產生屏障，阻止抗菌劑到達微生物細胞，或產生產生抵消抗菌劑作用的酵素的能力。

過度使用抗生素對抗生素抗藥性影響很大。抗生素過度使用對抗生素抗藥性影響很大。如果抗生素治療時間太短、無效或不適合特定感染疾病，那麼有彈性的微生物可能會持續存在。此外，對於感冒和流感等病毒感染疾病以及對抗生素沒有反應的小病，通常會不必要地開出抗生素。過度處方會使細菌不必要地接觸抗生素，並增加抗藥性細菌的風險。

目錄

第1章 簡介

第2章 執行摘要

第3章 市場概況

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資機會
  • 波特五力分析
  • 市場動態
    • 促進因素
      • 抗生素的過度使用和濫用
      • 抗生素抗藥性病菌感染增加
      • 抗菌素抗藥性負擔日益加重
    • 抑制因素
      • 全球缺乏對抗抗菌素抗藥性的創新抗生素
    • 機會
      • 全球對抗抗菌素抗藥性（AMR）的配合措施迅速加強

第4章 抗菌素抗藥性市場：依藥物類別

  • 概述
  • 聯合治療
  • 四環素類抗生素
  • 頭孢菌素
  • 胜肽和脂肪胜肽
  • Oxazolidinone系列
  • 其他

第5章 抗菌素抗藥性市場：依病原體分類

  • 概述
  • 大腸桿菌
  • 肺炎克雷伯菌
  • 銅綠假單胞菌
  • 金黃色葡萄球菌
  • 腸球菌屬
  • 其他

第6章 抗菌素抗藥性市場：依跡象分類

  • 概述
  • 併發症尿道感染（cUTI）
  • 血流感染疾病
  • 急性細菌性皮膚和皮膚結構感染疾病（ABSSSI）
  • 院內獲得性細菌性肺炎和人工呼吸器獲得性細菌性肺炎（HABP 和 VABP）
  • 社區型肺炎（CAP）
  • 其他

第7章 抗菌素抗藥性市場：按作用機制

  • 概述
  • 蛋白質合成抑制劑
  • 細胞壁合成抑制劑
  • 其他

第8章 抗菌素抗藥性市場：依地區

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 其他
  • 拉丁美洲、中東、非洲
    • 巴西
    • 沙烏地阿拉伯
    • 南非
    • 其他

第9章 競爭形勢

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭儀表板
  • 競爭熱圖
  • 2022年主要企業定位

第10章 公司簡介

  • Alkem Laboratories Ltd.
  • Pfizer Inc.
  • Acurx Pharmaceuticals, Inc.
  • Basilea Pharmaceutica Ltd
  • Cumberland Pharmaceuticals
  • Wockhardt Limited.
  • Paratek Pharmaceuticals Inc
  • Nabriva Therapeutics plc
  • Innoviva, Inc
  • Merck & Co., Inc.
Product Code: A180214

The antimicrobial resistance market is likely to experience a significant growth rate of 7.6% from 2023-2032 owing to increasing market demand from pharmaceutical sector - Allied Market Research

Antimicrobial Resistance Market - IMG1

Resistance to antimicrobials often develops in microorganisms over time because of genetic changes that occur during their reproductive cycles. Changes in the DNA may result in barriers that prevent antimicrobials from reaching the cell of microbe or may develop the ability to create enzymes that are able to counteract effects of the antimicrobial.

Antimicrobial resistance is significantly influenced by the overuse of antibiotics. Resistance to antimicrobials is heavily influenced by the excessive use of antibiotics. There is a higher chance of leaving behind resilient microbes when antibiotic treatments are too short, weak, or inappropriate for the specific infection. Moreover, antibiotics are often prescribed unnecessarily for viral infections such as colds, flu, or mild illnesses, which do not respond to antibiotics. Overprescribing leads to the unnecessary exposure of bacteria to these drugs, increasing the risk of resistance.

In addition, repeated exposure of microbes to antimicrobials, as well as contact with other already resistant microbes, provides numerous opportunities for resistance to develop and spread. Therefore, it is crucial to use antimicrobials appropriately to minimize the risk of antimicrobial resistance.

Furthermore, the rise in government initiatives to combat this antimicrobial resistance is the key factor which boosts the growth of the antimicrobial resistance market. For instance, the Global Antimicrobial Resistance Research & Development (AMR R&D) Hub is a collaboration of governments, non-governmental donor organizations, and intergovernmental organizations that use a One Health strategy to solve difficulties and increase coordination and collaboration in global AMR R&D.

On the other hand, the high cost of these novel therapeutics is expected to act as a restraint to the market growth. R&D of these antimicrobial candidates is expensive leading to higher cost of the products. This becomes difficult for people in lower-income countries to afford high-cost advanced antimicrobials and avoid antimicrobial resistance which may hinder market growth to some extent.

However, robust pipeline of antibiotic treatments to combat antimicrobial resistance is expected to offer lucrative opportunities for the growth of the market during the forecast period. Researchers and pharmaceutical companies have developed innovative therapies and treatments to combat antimicrobial resistance, providing potential new treatment options. In addition, the development of innovative antibiotics offers healthcare providers a wider range of treatment options. Having multiple effective antibiotics with different mechanisms of action can improve the chances of successfully treating infections, even those caused by highly resistant bacteria. This is expected to effectively overcome the threat of antimicrobial resistance and thus contribute to market growth during the forecast period.

The antimicrobial resistance market is segmented on the basis of drug class, pathogen, indication, mechanism of action, and region. On the basis of drug class, the market is classified into combination therapies, tetracyclines, cephalosporins, glycopeptides and lipoglycopeptides, oxazolidinones and others. On the basis of pathogen, the market is segmented into E. coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, Enterococcus Spp and others.

On the basis of on disease type, the market is segmented into complicated urinary tract infections (cUTI), blood stream infections, acute bacterial skin and skin structure infections (ABSSSI), hospital acquired bacterial pneumonia and ventilator acquired bacterial pneumonia (HABP and VABP), community acquired pneumonia (CAP) and Others. On the basis of mechanism of action, the market is categorized into protein synthesis inhibitors, cell wall synthesis inhibitors, and others. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global antimicrobial resistance market are Alkem Laboratories Ltd, Innoviva, Inc., Pfizer Inc., Merck & Co., Inc., Acurx Pharmaceuticals, Inc., Basilea Pharmaceutica Ltd, Cumberland Pharmaceuticals Inc., Wockhardt Limited, Paratek Pharmaceuticals, Inc., and Nabriva Therapeutics plc.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the antimicrobial resistance market analysis from 2022 to 2032 to identify the prevailing antimicrobial resistance market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the antimicrobial resistance market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global antimicrobial resistance market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data

Key Market Segments

By Indication

  • Complicated Urinary Tract Infections (cUTI)
  • Blood stream infections
  • Acute bacterial skin and skin structure infections (ABSSSI)
  • Hospital acquired bacterial pneumonia and ventilator acquired bacterial pneumonia (HABP and VABP)
  • Community acquired pneumonia (CAP)
  • Others

By Drug Class

  • Combination therapies
  • Tetracyclines
  • Cephalosporins
  • Glycopeptides and Lipoglycopeptides
  • Oxazolidinones
  • Others

By Mechanism of Action

  • Protein Synthesis Inhibitors
  • Cell Wall Synthesis Inhibitors
  • Others

By Pathogen

  • Klebsiella pneumoniae
  • Pseudomonas aeruginosa
  • Staphylococcus aureus
  • Enterococcus Spp
  • Others
  • Escherichia coli

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Pfizer Inc.
    • Cumberland Pharmaceuticals
    • Acurx Pharmaceuticals, Inc.
    • Paratek Pharmaceuticals Inc
    • Alkem Laboratories Ltd.
    • Nabriva Therapeutics plc
    • Innoviva, Inc
    • Basilea Pharmaceutica Ltd
    • Wockhardt Limited.
    • Merck & Co., Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Low bargaining power of suppliers
    • 3.3.2. Low threat of new entrants
    • 3.3.3. Low threat of substitutes
    • 3.3.4. Low intensity of rivalry
    • 3.3.5. Low bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Overuse and misuse of antibiotics
      • 3.4.1.2. Rise in prevalence of antimicrobial resistance bacterial infections
      • 3.4.1.3. Growth in burden of antimicrobial resistance
    • 3.4.2. Restraints
      • 3.4.2.1. Global shortage of innovative antibiotics to combat antimicrobial resistance
    • 3.4.3. Opportunities
      • 3.4.3.1. Surge in initiative to tackle antimicrobial resistance (AMR) globally

CHAPTER 4: ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Combination therapies
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Tetracyclines
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Cephalosporins
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Glycopeptides and Lipoglycopeptides
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country
  • 4.6. Oxazolidinones
    • 4.6.1. Key market trends, growth factors and opportunities
    • 4.6.2. Market size and forecast, by region
    • 4.6.3. Market share analysis by country
  • 4.7. Others
    • 4.7.1. Key market trends, growth factors and opportunities
    • 4.7.2. Market size and forecast, by region
    • 4.7.3. Market share analysis by country

CHAPTER 5: ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Escherichia coli
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Klebsiella pneumoniae
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Pseudomonas aeruginosa
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Staphylococcus aureus
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country
  • 5.6. Enterococcus Spp
    • 5.6.1. Key market trends, growth factors and opportunities
    • 5.6.2. Market size and forecast, by region
    • 5.6.3. Market share analysis by country
  • 5.7. Others
    • 5.7.1. Key market trends, growth factors and opportunities
    • 5.7.2. Market size and forecast, by region
    • 5.7.3. Market share analysis by country

CHAPTER 6: ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Complicated Urinary Tract Infections (cUTI)
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Blood stream infections
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Acute bacterial skin and skin structure infections (ABSSSI)
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country
  • 6.5. Hospital acquired bacterial pneumonia and ventilator acquired bacterial pneumonia (HABP and VABP)
    • 6.5.1. Key market trends, growth factors and opportunities
    • 6.5.2. Market size and forecast, by region
    • 6.5.3. Market share analysis by country
  • 6.6. Community acquired pneumonia (CAP)
    • 6.6.1. Key market trends, growth factors and opportunities
    • 6.6.2. Market size and forecast, by region
    • 6.6.3. Market share analysis by country
  • 6.7. Others
    • 6.7.1. Key market trends, growth factors and opportunities
    • 6.7.2. Market size and forecast, by region
    • 6.7.3. Market share analysis by country

CHAPTER 7: ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION

  • 7.1. Overview
    • 7.1.1. Market size and forecast
  • 7.2. Protein Synthesis Inhibitors
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by region
    • 7.2.3. Market share analysis by country
  • 7.3. Cell Wall Synthesis Inhibitors
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by region
    • 7.3.3. Market share analysis by country
  • 7.4. Others
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by region
    • 7.4.3. Market share analysis by country

CHAPTER 8: ANTIMICROBIAL RESISTANCE MARKET, BY REGION

  • 8.1. Overview
    • 8.1.1. Market size and forecast By Region
  • 8.2. North America
    • 8.2.1. Key market trends, growth factors and opportunities
    • 8.2.2. Market size and forecast, by Drug Class
    • 8.2.3. Market size and forecast, by Pathogen
    • 8.2.4. Market size and forecast, by Indication
    • 8.2.5. Market size and forecast, by Mechanism of Action
    • 8.2.6. Market size and forecast, by country
      • 8.2.6.1. U.S.
      • 8.2.6.1.1. Market size and forecast, by Drug Class
      • 8.2.6.1.2. Market size and forecast, by Pathogen
      • 8.2.6.1.3. Market size and forecast, by Indication
      • 8.2.6.1.4. Market size and forecast, by Mechanism of Action
      • 8.2.6.2. Canada
      • 8.2.6.2.1. Market size and forecast, by Drug Class
      • 8.2.6.2.2. Market size and forecast, by Pathogen
      • 8.2.6.2.3. Market size and forecast, by Indication
      • 8.2.6.2.4. Market size and forecast, by Mechanism of Action
      • 8.2.6.3. Mexico
      • 8.2.6.3.1. Market size and forecast, by Drug Class
      • 8.2.6.3.2. Market size and forecast, by Pathogen
      • 8.2.6.3.3. Market size and forecast, by Indication
      • 8.2.6.3.4. Market size and forecast, by Mechanism of Action
  • 8.3. Europe
    • 8.3.1. Key market trends, growth factors and opportunities
    • 8.3.2. Market size and forecast, by Drug Class
    • 8.3.3. Market size and forecast, by Pathogen
    • 8.3.4. Market size and forecast, by Indication
    • 8.3.5. Market size and forecast, by Mechanism of Action
    • 8.3.6. Market size and forecast, by country
      • 8.3.6.1. Germany
      • 8.3.6.1.1. Market size and forecast, by Drug Class
      • 8.3.6.1.2. Market size and forecast, by Pathogen
      • 8.3.6.1.3. Market size and forecast, by Indication
      • 8.3.6.1.4. Market size and forecast, by Mechanism of Action
      • 8.3.6.2. France
      • 8.3.6.2.1. Market size and forecast, by Drug Class
      • 8.3.6.2.2. Market size and forecast, by Pathogen
      • 8.3.6.2.3. Market size and forecast, by Indication
      • 8.3.6.2.4. Market size and forecast, by Mechanism of Action
      • 8.3.6.3. UK
      • 8.3.6.3.1. Market size and forecast, by Drug Class
      • 8.3.6.3.2. Market size and forecast, by Pathogen
      • 8.3.6.3.3. Market size and forecast, by Indication
      • 8.3.6.3.4. Market size and forecast, by Mechanism of Action
      • 8.3.6.4. Italy
      • 8.3.6.4.1. Market size and forecast, by Drug Class
      • 8.3.6.4.2. Market size and forecast, by Pathogen
      • 8.3.6.4.3. Market size and forecast, by Indication
      • 8.3.6.4.4. Market size and forecast, by Mechanism of Action
      • 8.3.6.5. Spain
      • 8.3.6.5.1. Market size and forecast, by Drug Class
      • 8.3.6.5.2. Market size and forecast, by Pathogen
      • 8.3.6.5.3. Market size and forecast, by Indication
      • 8.3.6.5.4. Market size and forecast, by Mechanism of Action
      • 8.3.6.6. Rest of Europe
      • 8.3.6.6.1. Market size and forecast, by Drug Class
      • 8.3.6.6.2. Market size and forecast, by Pathogen
      • 8.3.6.6.3. Market size and forecast, by Indication
      • 8.3.6.6.4. Market size and forecast, by Mechanism of Action
  • 8.4. Asia-Pacific
    • 8.4.1. Key market trends, growth factors and opportunities
    • 8.4.2. Market size and forecast, by Drug Class
    • 8.4.3. Market size and forecast, by Pathogen
    • 8.4.4. Market size and forecast, by Indication
    • 8.4.5. Market size and forecast, by Mechanism of Action
    • 8.4.6. Market size and forecast, by country
      • 8.4.6.1. Japan
      • 8.4.6.1.1. Market size and forecast, by Drug Class
      • 8.4.6.1.2. Market size and forecast, by Pathogen
      • 8.4.6.1.3. Market size and forecast, by Indication
      • 8.4.6.1.4. Market size and forecast, by Mechanism of Action
      • 8.4.6.2. China
      • 8.4.6.2.1. Market size and forecast, by Drug Class
      • 8.4.6.2.2. Market size and forecast, by Pathogen
      • 8.4.6.2.3. Market size and forecast, by Indication
      • 8.4.6.2.4. Market size and forecast, by Mechanism of Action
      • 8.4.6.3. India
      • 8.4.6.3.1. Market size and forecast, by Drug Class
      • 8.4.6.3.2. Market size and forecast, by Pathogen
      • 8.4.6.3.3. Market size and forecast, by Indication
      • 8.4.6.3.4. Market size and forecast, by Mechanism of Action
      • 8.4.6.4. Australia
      • 8.4.6.4.1. Market size and forecast, by Drug Class
      • 8.4.6.4.2. Market size and forecast, by Pathogen
      • 8.4.6.4.3. Market size and forecast, by Indication
      • 8.4.6.4.4. Market size and forecast, by Mechanism of Action
      • 8.4.6.5. South Korea
      • 8.4.6.5.1. Market size and forecast, by Drug Class
      • 8.4.6.5.2. Market size and forecast, by Pathogen
      • 8.4.6.5.3. Market size and forecast, by Indication
      • 8.4.6.5.4. Market size and forecast, by Mechanism of Action
      • 8.4.6.6. Rest of Asia-Pacific
      • 8.4.6.6.1. Market size and forecast, by Drug Class
      • 8.4.6.6.2. Market size and forecast, by Pathogen
      • 8.4.6.6.3. Market size and forecast, by Indication
      • 8.4.6.6.4. Market size and forecast, by Mechanism of Action
  • 8.5. LAMEA
    • 8.5.1. Key market trends, growth factors and opportunities
    • 8.5.2. Market size and forecast, by Drug Class
    • 8.5.3. Market size and forecast, by Pathogen
    • 8.5.4. Market size and forecast, by Indication
    • 8.5.5. Market size and forecast, by Mechanism of Action
    • 8.5.6. Market size and forecast, by country
      • 8.5.6.1. Brazil
      • 8.5.6.1.1. Market size and forecast, by Drug Class
      • 8.5.6.1.2. Market size and forecast, by Pathogen
      • 8.5.6.1.3. Market size and forecast, by Indication
      • 8.5.6.1.4. Market size and forecast, by Mechanism of Action
      • 8.5.6.2. Saudi Arabia
      • 8.5.6.2.1. Market size and forecast, by Drug Class
      • 8.5.6.2.2. Market size and forecast, by Pathogen
      • 8.5.6.2.3. Market size and forecast, by Indication
      • 8.5.6.2.4. Market size and forecast, by Mechanism of Action
      • 8.5.6.3. South Africa
      • 8.5.6.3.1. Market size and forecast, by Drug Class
      • 8.5.6.3.2. Market size and forecast, by Pathogen
      • 8.5.6.3.3. Market size and forecast, by Indication
      • 8.5.6.3.4. Market size and forecast, by Mechanism of Action
      • 8.5.6.4. Rest of LAMEA
      • 8.5.6.4.1. Market size and forecast, by Drug Class
      • 8.5.6.4.2. Market size and forecast, by Pathogen
      • 8.5.6.4.3. Market size and forecast, by Indication
      • 8.5.6.4.4. Market size and forecast, by Mechanism of Action

CHAPTER 9: COMPETITIVE LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top winning strategies
  • 9.3. Product Mapping of Top 10 Player
  • 9.4. Competitive Dashboard
  • 9.5. Competitive Heatmap
  • 9.6. Top player positioning, 2022

CHAPTER 10: COMPANY PROFILES

  • 10.1. Alkem Laboratories Ltd.
    • 10.1.1. Company overview
    • 10.1.2. Key Executives
    • 10.1.3. Company snapshot
    • 10.1.4. Operating business segments
    • 10.1.5. Product portfolio
    • 10.1.6. Business performance
    • 10.1.7. Key strategic moves and developments
  • 10.2. Pfizer Inc.
    • 10.2.1. Company overview
    • 10.2.2. Key Executives
    • 10.2.3. Company snapshot
    • 10.2.4. Operating business segments
    • 10.2.5. Product portfolio
    • 10.2.6. Business performance
    • 10.2.7. Key strategic moves and developments
  • 10.3. Acurx Pharmaceuticals, Inc.
    • 10.3.1. Company overview
    • 10.3.2. Key Executives
    • 10.3.3. Company snapshot
    • 10.3.4. Operating business segments
    • 10.3.5. Product portfolio
  • 10.4. Basilea Pharmaceutica Ltd
    • 10.4.1. Company overview
    • 10.4.2. Key Executives
    • 10.4.3. Company snapshot
    • 10.4.4. Operating business segments
    • 10.4.5. Product portfolio
    • 10.4.6. Business performance
  • 10.5. Cumberland Pharmaceuticals
    • 10.5.1. Company overview
    • 10.5.2. Key Executives
    • 10.5.3. Company snapshot
    • 10.5.4. Operating business segments
    • 10.5.5. Product portfolio
    • 10.5.6. Business performance
    • 10.5.7. Key strategic moves and developments
  • 10.6. Wockhardt Limited.
    • 10.6.1. Company overview
    • 10.6.2. Key Executives
    • 10.6.3. Company snapshot
    • 10.6.4. Operating business segments
    • 10.6.5. Product portfolio
    • 10.6.6. Business performance
  • 10.7. Paratek Pharmaceuticals Inc
    • 10.7.1. Company overview
    • 10.7.2. Key Executives
    • 10.7.3. Company snapshot
    • 10.7.4. Operating business segments
    • 10.7.5. Product portfolio
    • 10.7.6. Business performance
  • 10.8. Nabriva Therapeutics plc
    • 10.8.1. Company overview
    • 10.8.2. Key Executives
    • 10.8.3. Company snapshot
    • 10.8.4. Operating business segments
    • 10.8.5. Product portfolio
    • 10.8.6. Business performance
    • 10.8.7. Key strategic moves and developments
  • 10.9. Innoviva, Inc
    • 10.9.1. Company overview
    • 10.9.2. Key Executives
    • 10.9.3. Company snapshot
    • 10.9.4. Operating business segments
    • 10.9.5. Product portfolio
    • 10.9.6. Business performance
  • 10.10. Merck & Co., Inc.
    • 10.10.1. Company overview
    • 10.10.2. Key Executives
    • 10.10.3. Company snapshot
    • 10.10.4. Operating business segments
    • 10.10.5. Product portfolio
    • 10.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 02. ANTIMICROBIAL RESISTANCE MARKET FOR COMBINATION THERAPIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. ANTIMICROBIAL RESISTANCE MARKET FOR TETRACYCLINES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. ANTIMICROBIAL RESISTANCE MARKET FOR CEPHALOSPORINS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. ANTIMICROBIAL RESISTANCE MARKET FOR GLYCOPEPTIDES AND LIPOGLYCOPEPTIDES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. ANTIMICROBIAL RESISTANCE MARKET FOR OXAZOLIDINONES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. ANTIMICROBIAL RESISTANCE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. GLOBAL ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
  • TABLE 09. ANTIMICROBIAL RESISTANCE MARKET FOR ESCHERICHIA COLI, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. ANTIMICROBIAL RESISTANCE MARKET FOR KLEBSIELLA PNEUMONIAE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. ANTIMICROBIAL RESISTANCE MARKET FOR PSEUDOMONAS AERUGINOSA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. ANTIMICROBIAL RESISTANCE MARKET FOR STAPHYLOCOCCUS AUREUS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. ANTIMICROBIAL RESISTANCE MARKET FOR ENTEROCOCCUS SPP, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. ANTIMICROBIAL RESISTANCE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 16. ANTIMICROBIAL RESISTANCE MARKET FOR COMPLICATED URINARY TRACT INFECTIONS (CUTI), BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. ANTIMICROBIAL RESISTANCE MARKET FOR BLOOD STREAM INFECTIONS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. ANTIMICROBIAL RESISTANCE MARKET FOR ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI), BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. ANTIMICROBIAL RESISTANCE MARKET FOR HOSPITAL ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR ACQUIRED BACTERIAL PNEUMONIA (HABP AND VABP), BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. ANTIMICROBIAL RESISTANCE MARKET FOR COMMUNITY ACQUIRED PNEUMONIA (CAP), BY REGION, 2022-2032 ($MILLION)
  • TABLE 21. ANTIMICROBIAL RESISTANCE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 22. GLOBAL ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 23. ANTIMICROBIAL RESISTANCE MARKET FOR PROTEIN SYNTHESIS INHIBITORS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 24. ANTIMICROBIAL RESISTANCE MARKET FOR CELL WALL SYNTHESIS INHIBITORS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 25. ANTIMICROBIAL RESISTANCE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 26. ANTIMICROBIAL RESISTANCE MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 27. NORTH AMERICA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 28. NORTH AMERICA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
  • TABLE 29. NORTH AMERICA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 30. NORTH AMERICA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 31. NORTH AMERICA ANTIMICROBIAL RESISTANCE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 32. U.S. ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 33. U.S. ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
  • TABLE 34. U.S. ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 35. U.S. ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 36. CANADA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 37. CANADA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
  • TABLE 38. CANADA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 39. CANADA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 40. MEXICO ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 41. MEXICO ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
  • TABLE 42. MEXICO ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 43. MEXICO ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 44. EUROPE ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 45. EUROPE ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
  • TABLE 46. EUROPE ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 47. EUROPE ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 48. EUROPE ANTIMICROBIAL RESISTANCE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 49. GERMANY ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 50. GERMANY ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
  • TABLE 51. GERMANY ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 52. GERMANY ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 53. FRANCE ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 54. FRANCE ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
  • TABLE 55. FRANCE ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 56. FRANCE ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 57. UK ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 58. UK ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
  • TABLE 59. UK ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 60. UK ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 61. ITALY ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 62. ITALY ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
  • TABLE 63. ITALY ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 64. ITALY ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 65. SPAIN ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 66. SPAIN ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
  • TABLE 67. SPAIN ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 68. SPAIN ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 69. REST OF EUROPE ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 70. REST OF EUROPE ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
  • TABLE 71. REST OF EUROPE ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 72. REST OF EUROPE ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 73. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 74. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
  • TABLE 75. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 76. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 77. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 78. JAPAN ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 79. JAPAN ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
  • TABLE 80. JAPAN ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 81. JAPAN ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 82. CHINA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 83. CHINA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
  • TABLE 84. CHINA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 85. CHINA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 86. INDIA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 87. INDIA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
  • TABLE 88. INDIA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 89. INDIA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 90. AUSTRALIA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 91. AUSTRALIA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
  • TABLE 92. AUSTRALIA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 93. AUSTRALIA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 94. SOUTH KOREA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 95. SOUTH KOREA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
  • TABLE 96. SOUTH KOREA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 97. SOUTH KOREA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 98. REST OF ASIA-PACIFIC ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 99. REST OF ASIA-PACIFIC ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
  • TABLE 100. REST OF ASIA-PACIFIC ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 101. REST OF ASIA-PACIFIC ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 102. LAMEA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 103. LAMEA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
  • TABLE 104. LAMEA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 105. LAMEA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 106. LAMEA ANTIMICROBIAL RESISTANCE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 107. BRAZIL ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 108. BRAZIL ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
  • TABLE 109. BRAZIL ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 110. BRAZIL ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 111. SAUDI ARABIA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 112. SAUDI ARABIA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
  • TABLE 113. SAUDI ARABIA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 114. SAUDI ARABIA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 115. SOUTH AFRICA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 116. SOUTH AFRICA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
  • TABLE 117. SOUTH AFRICA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 118. SOUTH AFRICA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 119. REST OF LAMEA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 120. REST OF LAMEA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
  • TABLE 121. REST OF LAMEA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 122. REST OF LAMEA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 123. ALKEM LABORATORIES LTD.: KEY EXECUTIVES
  • TABLE 124. ALKEM LABORATORIES LTD.: COMPANY SNAPSHOT
  • TABLE 125. ALKEM LABORATORIES LTD.: PRODUCT SEGMENTS
  • TABLE 126. ALKEM LABORATORIES LTD.: PRODUCT PORTFOLIO
  • TABLE 127. ALKEM LABORATORIES LTD.: KEY STRATERGIES
  • TABLE 128. PFIZER INC.: KEY EXECUTIVES
  • TABLE 129. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 130. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 131. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 132. PFIZER INC.: KEY STRATERGIES
  • TABLE 133. ACURX PHARMACEUTICALS, INC.: KEY EXECUTIVES
  • TABLE 134. ACURX PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
  • TABLE 135. ACURX PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
  • TABLE 136. ACURX PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
  • TABLE 137. BASILEA PHARMACEUTICA LTD: KEY EXECUTIVES
  • TABLE 138. BASILEA PHARMACEUTICA LTD: COMPANY SNAPSHOT
  • TABLE 139. BASILEA PHARMACEUTICA LTD: PRODUCT SEGMENTS
  • TABLE 140. BASILEA PHARMACEUTICA LTD: PRODUCT PORTFOLIO
  • TABLE 141. CUMBERLAND PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 142. CUMBERLAND PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 143. CUMBERLAND PHARMACEUTICALS: PRODUCT SEGMENTS
  • TABLE 144. CUMBERLAND PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 145. CUMBERLAND PHARMACEUTICALS: KEY STRATERGIES
  • TABLE 146. WOCKHARDT LIMITED.: KEY EXECUTIVES
  • TABLE 147. WOCKHARDT LIMITED.: COMPANY SNAPSHOT
  • TABLE 148. WOCKHARDT LIMITED.: PRODUCT SEGMENTS
  • TABLE 149. WOCKHARDT LIMITED.: PRODUCT PORTFOLIO
  • TABLE 150. PARATEK PHARMACEUTICALS INC: KEY EXECUTIVES
  • TABLE 151. PARATEK PHARMACEUTICALS INC: COMPANY SNAPSHOT
  • TABLE 152. PARATEK PHARMACEUTICALS INC: PRODUCT SEGMENTS
  • TABLE 153. PARATEK PHARMACEUTICALS INC: PRODUCT PORTFOLIO
  • TABLE 154. NABRIVA THERAPEUTICS PLC: KEY EXECUTIVES
  • TABLE 155. NABRIVA THERAPEUTICS PLC: COMPANY SNAPSHOT
  • TABLE 156. NABRIVA THERAPEUTICS PLC: PRODUCT SEGMENTS
  • TABLE 157. NABRIVA THERAPEUTICS PLC: PRODUCT PORTFOLIO
  • TABLE 158. NABRIVA THERAPEUTICS PLC: KEY STRATERGIES
  • TABLE 159. INNOVIVA, INC: KEY EXECUTIVES
  • TABLE 160. INNOVIVA, INC: COMPANY SNAPSHOT
  • TABLE 161. INNOVIVA, INC: PRODUCT SEGMENTS
  • TABLE 162. INNOVIVA, INC: PRODUCT PORTFOLIO
  • TABLE 163. MERCK & CO., INC.: KEY EXECUTIVES
  • TABLE 164. MERCK & CO., INC.: COMPANY SNAPSHOT
  • TABLE 165. MERCK & CO., INC.: PRODUCT SEGMENTS
  • TABLE 166. MERCK & CO., INC.: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. ANTIMICROBIAL RESISTANCE MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF ANTIMICROBIAL RESISTANCE MARKET,2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN ANTIMICROBIAL RESISTANCE MARKET (2023-2032)
  • FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW THREAT OF NEW ENTRANTS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. LOW INTENSITY OF RIVALRY
  • FIGURE 08. LOW BARGAINING POWER OF BUYERS
  • FIGURE 09. GLOBAL ANTIMICROBIAL RESISTANCE MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 10. ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022 AND 2032(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR COMBINATION THERAPIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR TETRACYCLINES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR CEPHALOSPORINS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR GLYCOPEPTIDES AND LIPOGLYCOPEPTIDES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR OXAZOLIDINONES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR ESCHERICHIA COLI, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR KLEBSIELLA PNEUMONIAE, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR PSEUDOMONAS AERUGINOSA, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR STAPHYLOCOCCUS AUREUS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR ENTEROCOCCUS SPP, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 24. ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022 AND 2032(%)
  • FIGURE 25. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR COMPLICATED URINARY TRACT INFECTIONS (CUTI), BY COUNTRY 2022 AND 2032(%)
  • FIGURE 26. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR BLOOD STREAM INFECTIONS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 27. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI), BY COUNTRY 2022 AND 2032(%)
  • FIGURE 28. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR HOSPITAL ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR ACQUIRED BACTERIAL PNEUMONIA (HABP AND VABP), BY COUNTRY 2022 AND 2032(%)
  • FIGURE 29. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR COMMUNITY ACQUIRED PNEUMONIA (CAP), BY COUNTRY 2022 AND 2032(%)
  • FIGURE 30. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 31. ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022 AND 2032(%)
  • FIGURE 32. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR PROTEIN SYNTHESIS INHIBITORS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 33. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR CELL WALL SYNTHESIS INHIBITORS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 34. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 35. ANTIMICROBIAL RESISTANCE MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 36. U.S. ANTIMICROBIAL RESISTANCE MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. CANADA ANTIMICROBIAL RESISTANCE MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. MEXICO ANTIMICROBIAL RESISTANCE MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. GERMANY ANTIMICROBIAL RESISTANCE MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. FRANCE ANTIMICROBIAL RESISTANCE MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. UK ANTIMICROBIAL RESISTANCE MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. ITALY ANTIMICROBIAL RESISTANCE MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. SPAIN ANTIMICROBIAL RESISTANCE MARKET, 2022-2032 ($MILLION)
  • FIGURE 44. REST OF EUROPE ANTIMICROBIAL RESISTANCE MARKET, 2022-2032 ($MILLION)
  • FIGURE 45. JAPAN ANTIMICROBIAL RESISTANCE MARKET, 2022-2032 ($MILLION)
  • FIGURE 46. CHINA ANTIMICROBIAL RESISTANCE MARKET, 2022-2032 ($MILLION)
  • FIGURE 47. INDIA ANTIMICROBIAL RESISTANCE MARKET, 2022-2032 ($MILLION)
  • FIGURE 48. AUSTRALIA ANTIMICROBIAL RESISTANCE MARKET, 2022-2032 ($MILLION)
  • FIGURE 49. SOUTH KOREA ANTIMICROBIAL RESISTANCE MARKET, 2022-2032 ($MILLION)
  • FIGURE 50. REST OF ASIA-PACIFIC ANTIMICROBIAL RESISTANCE MARKET, 2022-2032 ($MILLION)
  • FIGURE 51. BRAZIL ANTIMICROBIAL RESISTANCE MARKET, 2022-2032 ($MILLION)
  • FIGURE 52. SAUDI ARABIA ANTIMICROBIAL RESISTANCE MARKET, 2022-2032 ($MILLION)
  • FIGURE 53. SOUTH AFRICA ANTIMICROBIAL RESISTANCE MARKET, 2022-2032 ($MILLION)
  • FIGURE 54. REST OF LAMEA ANTIMICROBIAL RESISTANCE MARKET, 2022-2032 ($MILLION)
  • FIGURE 55. TOP WINNING STRATEGIES, BY YEAR (2020-2023)
  • FIGURE 56. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)
  • FIGURE 57. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)
  • FIGURE 58. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 59. COMPETITIVE DASHBOARD
  • FIGURE 60. COMPETITIVE HEATMAP: ANTIMICROBIAL RESISTANCE MARKET
  • FIGURE 61. TOP PLAYER POSITIONING, 2022
  • FIGURE 62. ALKEM LABORATORIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 63. ALKEM LABORATORIES LTD.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 64. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 65. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 66. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 67. BASILEA PHARMACEUTICA LTD: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 68. BASILEA PHARMACEUTICA LTD: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 69. CUMBERLAND PHARMACEUTICALS: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 70. WOCKHARDT LIMITED.: NET REVENUE, 2021-2023 ($MILLION)
  • FIGURE 71. WOCKHARDT LIMITED.: REVENUE SHARE BY REGION, 2023 (%)
  • FIGURE 72. PARATEK PHARMACEUTICALS INC: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 73. NABRIVA THERAPEUTICS PLC: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 74. INNOVIVA, INC: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 75. MERCK & CO., INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 76. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 77. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2022 (%)